Stock Events

Stock Events

Cg Oncology 

$78.69
20
+$1.08+1.39% 08:24 Today

Statistics

Day High
77.75
Day Low
77.61
52W High
80.97
52W Low
24.85
Volume
26,180
Avg. Volume
-
Mkt Cap
6.88B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.9
-0.72
-0.53
-0.35
Expected EPS
-0.834112
Actual EPS
N/A

Financials

-3,985.02%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
4.04MRevenue
-161MNet Income

Analyst Ratings

87.50Average Price Target
The highest estimate is 100.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGON. It's not an investment recommendation.
Apple
7
AAPL
Microsoft
7
MSFT
Tesla
7
TSLA
NVIDIA
7
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb is involved in developing cancer immunotherapies, directly competing in the oncology space.
Merck
MRK
Mkt Cap335.14B
Merck is known for its strong portfolio in oncology, including immunotherapy drugs that compete in similar markets as CG Oncology.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad range of cancer treatments, including vaccines and advanced biologics, competing in the oncology sector.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca focuses on various cancer drugs, including those for conditions directly targeted by CG Oncology's pipeline.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, through its acquisition of Kite Pharma, has become a significant player in the cancer therapy field, overlapping with CG Oncology's focus areas.
Novartis
NVS
Mkt Cap286.78B
Novartis offers advanced cancer treatments, including gene therapy and immunotherapy, competing in the same therapeutic areas as CG Oncology.
AMGEN
AMGN
Mkt Cap224.63B
Amgen develops targeted therapies and immunotherapies for cancer, aligning them as a competitor in the oncology market.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, with its extensive cancer drug portfolio, competes directly in the oncology market, impacting CG Oncology's market share.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals focuses on innovative biologics in oncology, which competes with CG Oncology's approach to cancer treatment.
Exelixis
EXEL
Mkt Cap12.7B
Exelixis is involved in the discovery, development, and commercialization of new cancer therapies, competing in similar therapeutic areas as CG Oncology.

About

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Show more...
CEO
Arthur Kuan
Employees
142
Country
United States
ISIN
US1569441009

Listings

XNAS
US
CGON
BOATS
BOATS
CGON.BOATS

0 Comments

Share your thoughts

FAQ

What is Cg Oncology stock price today?▼
The current price of CGON is $78.69 USD — it has increased by +1.39% in the past 24 hours. Watch Cg Oncology stock price performance more closely on the chart.
What is Cg Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cg Oncology stocks are traded under the ticker CGON.
Is Cg Oncology stock price growing?▼
CGON stock has risen by +3.44% compared to the previous week, the month change is a +8.21% rise, over the last year Cg Oncology has showed a +198.73% increase.
What is Cg Oncology market cap?▼
Today Cg Oncology has the market capitalization of 6.88B
When is the next Cg Oncology earnings date?▼
Cg Oncology is going to release the next earnings report on November 12, 2026.
What were Cg Oncology earnings last quarter?▼
CGON earnings for the last quarter are -0.9 USD per share, whereas the estimation was -0.66 USD resulting in a -35.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cg Oncology revenue for the last year?▼
Cg Oncology revenue for the last year amounts to 4.04M USD.
What is Cg Oncology net income for the last year?▼
CGON net income for the last year is -161M USD.
How many employees does Cg Oncology have?▼
As of August 21, 2026, the company has 142 employees.
In which sector is Cg Oncology located?▼
Cg Oncology operates in the Health & Wellness sector.
When did Cg Oncology complete a stock split?▼
Cg Oncology has not had any recent stock splits.
Where is Cg Oncology headquartered?▼
Cg Oncology is headquartered in DALLAS, United States.